Johnson & Johnson's (JNJ.US) Nivolumab Injection is proposed to be included in the priority review
Tuesday, Nov 12, 2024 1:00 am ET
1min read On November 12, the CDE's website announced that Johnson & Johnson's (JNJ.US) Nipocalimab injection was proposed to be included in the priority review, which is indicated for the treatment of adult and adolescent patients (aged 12 and above) with generalized myasthenia gravis (gMG) who test positive for autoantibodies. Nipocalimab is an FcRn antibody developed by Johnson & Johnson through the acquisition of Momenta Pharmaceuticals for approximately $6.5 billion. The drug has already been submitted for approval in the US in August this year for myasthenia gravis. This time being included in the proposed priority review by the CDE means it is also expected to be approved in China soon.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.